. However, the value of the assay in attempts to alter the disease course remains uncertain (Smallwood et al., 1984; Trotter et al., 1984; Nomura et al., 1989) .
The other characteristics of tumour cells that may also lead to a final lethal event are rarely, if ever, considered in the design of new treatments. Yet there is evidence that the tumours' interaction with its host can be lethal by means of its metastatic properties or by means of its host-suppressive property (Briozzo et al., 1988; Pourreau-Schneider et al., 1989) . Since Specimens were collected into 20 ml of growth medium admixed with 15% foetal bovine serum (KC Biological, Lenexa, KS). Single-cell suspensions were prepared and cultured, and cultures scored as previously described (Hug et al., 1984) . For hormone-supplemented conditions, 5 x 10-7 M 17-beta-estradiol, 10 microgram ml-' insulin, 2.5 microgram ml-' hydrocortisone, and 50 ng ml-' epidermal growth factor were added to both culture layers. 
Results
The characteristics of patients were as follows: 107 patients could be evaluated. One patient was lost to follow-up, and the cultures of two patients were contaminated with bacterial overgrowth. The median performance status of patients (using the Zubrod scale) was one and ranged from 0-4. The median number of organ sites involved with tumour was two and ranged from 1-5. Twenty-seven patients had received one prior chemotherapy treatment: 25 preoperatively to reduce the tumour to operable size, two as first treatment for distant disease. All others had received two or more prior chemotherapy treatments.
The median survival of patients was 12 months. The two conventional prognostic factors for survival, i.e. performance status (estimated by the Zubrod scale) and disease extent (estimated by the number of organ sites involved with tumour metastases) separated our patients into groups of distinctive prognosis (Figure la and b) . The two conventional prognostic factors in combination, expressed as 'predictive score' (Table I) , separated the patients even more distinctly into groups of different survival. tically significant; and even then it was observed only under hormone-supplemented culture conditions (see Figure 2a) , not under conventional conditions (see Figure 2b) . If, however, we separated groups by the 'predictive score' (Table I), increasing clonogenicity under hormone-supplemented conditions correlated with decreasing survival in two. Surprisingly, patients with tumours of low clonogenicity (<0.002% under conventional culture conditions and <0.01% under hormone-supplemented conditions) had the shortest survival. Patients with tumours of low clonogenicity comprised 23% of all patients; and 25% of tumours evaluated were low clonogenic.
We compared cell viability and percentage of tumour cells contained in the single-cell suspensions among specimens that yielded scant tumour growth and specimens that yielded abundant tumour growth. We found that fewer viable tumour cells had been set into the cultures that yielded scant growth than were set into those cultures that yielded abun- patients with higher tumour clonogenicity. For patients with 0.8-* 8 20 higher tumour clonogenicity a weak inverse association of clonogenicity and survival of patients did exist, but this inverse association could be observed only for clonogenicity determined under hormone-supplemented culture conditions. 0.6-Similar inverse associations between tumour clonogenicity and patient survival have been observed previously, for patients with breast tumours and for patients with other solid tumours (Giovanni et al., 1988 There are also tumour-biological principles that may explain our inability to recover the most virulent tumour subpopulations. As the disease progresses some tumour cell clones will escape endocrine control, and paracrine factors, such as matrix substances or secretory products from supportive stromal cells, may regulate tumour cell proliferation. Thus, stromal cells release the cytokines necessary for tumour cell adherence, invasion, and proliferation, while matrix elements transmit environmental growth signals to the nucleus. That we failed to include these components in our culture system may explain our inability to recovery all tumour cell subpopulations. This would suggest that not only the ability of tumour cells to proliferate, but also their ability to metastasise and to suppress host reactivity, influences the disease outcome.
An alternative explanation for our inability to recover the biologically most relevant tumour subclones may be the possibility that in vivo tumour growth is primarily determined by growth inhibitors (Arteaga et al., 1988) , while in vitro tumour growth is primarily determined by growth stimulatory substances (Yee et al., 1988; Osborne et al., 1989; Cormier et al., 1989) . Thus, using stimulators of growth could result in in vitro tumour growth that has no bearing to the in vivo tumour growth.
Regardless of which explanation is closest to the truth, it is safe to conclude that the proliferative ability of tumour cells, measured by their clonogenicity under regular and under hormone-enriched culture conditions, is not the only and certainly not the most important feature of tumour cells that controls the clinical course of the disease.
